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Abstract 
Iron(III)-polymaltose pharmaceutical ferritin analogue Ferrifol® was investigated by high 
resolution transmission electron microscopy (HRTEM), X-ray diffraction, thermogravimetry, 
electron magnetic resonance (EMR) spectroscopy, dc magnetization measurements and 
57
Fe 
Mössbauer spectroscopy to get novel information about the structural arrangement of the iron core. 
The Ferrifol® Mössbauer spectra measured in the range from 295 to 90 K demonstrated non-
Lorentzian two-peak pattern. These spectra were better fitted using a superposition of 5 quadrupole 
doublets with the same line width. The obtained Mössbauer parameters were different and an 
unusual line broadening with temperature decrease was observed. Measurements of the Ferrifol® 
Mössbauer spectra from 60 to 20 K demonstrated a slow decrease of magnetic relaxation in the iron 
core. Zero-field-cooled and field-cooled magnetization measurements revealed a blocking 
temperature at ~33 K and paramagnetic state of the Ferrifol® iron core at higher temperatures. 
Isothermal magnetization measurements at 5 K show that the saturation magnetic moment is ~0.31 
emu/g. X-band EMR spectroscopy measurements revealed the presence of different magnetic 
species in the sample. Transmission electron microscopy demonstrated that the size of the iron 
cores in Ferrifol® is in the range 2–6 nm. The lattice periodicity in these iron cores, measured on 
the HRTEM images, appeared to be vary in the range 2.2–2.7 Å. This can be best understood as sets 
of close packed O(OH) layers in ferrihydrite cores without long range correlation. 
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Introduction 
 
Iron is an essential element for living systems which is involved in many biological processes 
from oxygen transport till electron transport. The organism’s needs in iron for iron-containing 
proteins synthesis are realized through iron deposition and release by iron storage protein ferritin. 
This macromolecule consists of spherical multi-subunit shell with an internal cavity of 10 nm which 
contains a nanosized ferrihydrite core (approximate formulae are 5Fe2O39H2O or 
(FeOOH)8(FeO:ОРО3Н2)) with up to 4500 Fe atoms (see reviews [1–8]). This protein deposits iron 
in non-toxic bioavailable form. However, iron deficiency resulting from various causes such as 
hereditary diseases, pregnancy, blood loss, insufficient dietary iron intake (nutritional deficiency), 
etc., leads to serious consequences for the organism and health known as iron deficiency anemia 
(see, for example, [9, 10]). Therefore, in the case of iron deficiency anemia an external source of 
iron is required. The most effective pharmaceuticals designed to replenish iron deficiency and treat 
anemia appeared to have a very close structure to ferritin with non-toxic iron, thus they can be 
supposed as ferritin synthetic analogues. These analogues also contain nanosized iron core in the 
forms of β-FeOOH or ferrihydrite as determined by their initial iron source before synthesis: the 
first form appeared in the presence of Cl
–
 ions, when FeCl2 was used for preparation. The obtained 
ferric hydrous oxide core was covered by protective polysaccharide shell imitating the ferritin coat 
in the native protein. Various polysaccharides can be used for the shell such as dextran, dextrin, 
polymaltose, etc. Manufactured iron(III)-oxyhidroxides–polysaccharide complexes can be produced 
as solutions for injections (for example, Imferon®), tablets and drops/syrup (for instance, 
Maltofer®). Note that the tablets containing iron(III)–polymaltose complexes appeared to be much 
more effective drugs for oral administration than tablets with ferrous compounds [11]. Therefore, 
ferritin pharmaceutical analogues are of interest for the study in comparison with the native protein.  
One of the most interesting problems in this case is associated with the iron core structure in 
both ferritin and its pharmaceutical analogues because it could be directly related to their biological 
functions and effectiveness for anemia treatment. Various structural investigations of ferritin iron 
cores by transmission electron microscopy (TEM), X-ray absorption spectroscopy and electron 
nanodiffraction resulted in a variety of iron core models [12–19]. Applications of magnetization and 
Mössbauer spectroscopy measurements in the study of various ferritins and its pharmaceutical 
analogues demonstrated spread approaches also (see, for example, [20–29], for review see [30–32]). 
Using Mössbauer spectroscopy in our earlier studies of ferritin and some pharmaceutical analogues 
(iron-dextran complexes including Imferon®, iron-polymaltose complexes Ferrum Lek and 
Maltofer®) we developed heterogeneous iron core models in order to fit their Mössbauer spectra, 
which implies different regions/layers in ferric hydrous oxide cores with corresponding different 
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quadrupole splitting mainly [33–42]. Moreover, recently we observed unusual temperature 
dependences of some Mössbauer parameters for ferritin and Ferrum Lek [39] and then for 
Maltofer® which were interpreted as a result of rearrangement of more and less close-packed 
FeOOH regions/layers in the iron cores [42]. Preliminary study of another iron-polymaltose 
complex Ferrifol® using Mössbauer spectroscopy at selected temperatures showed similar 
anomalies [41, 43] which must be analyzed in detail. Therefore, in this work we present extended 
studies of the iron core in Ferrifol® by means of high resolution TEM (HRTEM), X-ray diffraction 
(XRD), thermogravimetry (TG), electron magnetic resonance (EMR) spectroscopy, dc 
magnetization measurements and 
57
Fe Mössbauer spectroscopy in a wide temperature range. 
 
Materials and methods 
 
Powdered sample of Ferrifol® (CTS Chemical Industries Ltd., Israel) was prepared from 
about 1/3 of tablet containing 100 mg of Fe. For Mössbauer measurements the Ferrifol® powder 
was placed into Plexiglas sample holder with a diameter of 2 cm and tightly pressed accounting the 
final sample thickness to be ~8 mg Fe/cm
2
. In some cases, 100 mg of powdered lyophilized human 
liver ferritin (prepared as shown in [34]) placed into similar sample holder was used as a reference 
material. 
TEM and HRTEM images of Ferrifol® and ferritin were obtained at the Centre for Energy 
Research (Budapest) using (i) a JEOL 3010 transmission electron microscope at 300 keV (LaB6 
cathode, 0.17 nm point-to-point resolution, UHR pole piece) equipped with GIF and (ii) a FEI‐
Themis 200 G3 transmission electron microscope at 200 keV with a CS corrected objective lens 
(FEG, point resolution is around 0.09 nm in HREM mode and 0.16 nm in STEM mode). 
Suspension samples for TEM analysis were prepared using distilled water. A drop of the resulting 
suspension was deposited onto ultrathin carbon coated gold TEM grid (Ted Pella). The HRTEM 
images were analyzed using the Digital Micrograph (Gatan Tridiem) software.  
X-ray powder diffraction of Ferrifol® powdered tablet was measured using the XRD–7000 
powder diffractometer (Shimadzu) operated at 40 kV and 30 mA with CuK radiation using a 
monochromator, scanned over 2 from 5 to 80 at the Ural Federal University (Ekaterinburg). 
Thermogravimetry of Ferrifol® was carried out using SETSYS Evolution (Setaram) at the 
Institute of Solid State Chemistry, Ural Branch of the Russian Academy of Sciences (Ekaterinburg) 
in order to have the weight of inorganic part for magnetization measurements. 
Magnetization measurements on 46.6 mg powdered Ferrifol® mounted in gel-caps were 
performed using a SQUID magnetometer MPMS-5S (Quantum Design) in the temperature range 
from 300 K to 5 K at the “Racah” Institute of Physics, the Hebrew University (Jerusalem). The 
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weight was further corrected for inorganic part only using our TG data. The differential SQUID 
sensitivity was 10
–7
 emu.  
X-band EMR spectroscopy measurements of Ferrifol® were performed at the Institute of 
Physics, Budapest University of Technology and Economics (Budapest), with a Bruker ElexSys 
E500 X-band spectrometer by recording the first derivative of the microwave absorption power 
with respect to the applied magnetic field. Measurements were carried out at temperatures in the 
range from 140 K to 290 K: (i) on 20 mg of powdered Ferrifol® sample at 290 K and (ii) on a 
sample prepared as a mixture of 20 mg of Ferrifol® powder with ~250 mg KBr powder, in order 
to avoid texture and orientation of magnetic particles. The conditions of EMR measurements 
involved a modulation frequency of 100 kHz, modulation amplitude of 1 G, microwave power of 
~2 mW and microwave frequency of f  9.3 GHz. The spectra were scanned in the field range of 
100–10900 G with a sweep time of ~84 s. The magnetic field axis of the obtained spectra was 
rescaled according to f0  9.33 GHz for further processing. Fitting and decomposition of EMR 
spectra was carried out by using the MossWinn software [44] that was complemented for this 
purpose with auxiliary libraries providing the fitting functions for the EMR signal of powders made 
of magnetic particles with either uniaxial or cubic magnetocrystalline anisotropy. 
57
Fe Mössbauer spectra of Ferrifol® were measured in the two different temperature ranges. 
In the range from 295 to 90 K we have used Mössbauer spectrometric system with a high velocity 
resolution, build on the base of SM-2201 spectrometer and temperature variable liquid nitrogen 
cryostat with moving absorber at the Ural Federal University (Ekaterinburg). This spectrometer 
operates with a saw-tooth shape velocity reference signal formed by the digital-analogue converter 
using discretization of 2
12
 (quantification using 4096 steps). Detailed description and the advances 
of this system were given in [45, 46] and references therein. The 
57Со(Rh) source of ~1.0×109 Bq 
(Ritverc GmbH, St. Petersburg, Russian Federation, an initial activity was of ~1.8×10
9
 Bq) was 
used at room temperature. The spectra were measured in transmission geometry and registered in 
4096 channels. Statistical count rates for Ferrifol® were in the range of (3.6–3.8)×105 counts per 
channel with the signal-to-noise ratios in the range from 113 to 137. The measured Mössbauer 
spectra were further computer fitted using the UNIVEM-MS program with a least squares 
procedure using the Lorentzian line shape. Parameters determined for the measured spectra were 
isomer shift, δ, quadrupole splitting, ΔEQ, line width, Γ, relative subspectrum area, A, and 
normalized statistical criterion of fitting quality χ2. The best fits were determined using differential 
spectrum (the difference between experimental and calculated spectra), χ2 and physical meaning of 
the spectral parameters. Calibration of the velocity scale and control of the velocity signal in the 
small velocity range were performed using the reference absorber of sodium nitroprusside (SNP) 
with a thickness of 5 mg Fe/cm
2
. The line shape of SNP was a pure Lorentzian and the  value 
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measured in 4096 channels was 0.2310.002 mm/s. The velocity resolution in the spectra measured 
by SM-2201 spectrometer in the small velocity range was of ~0.001 mm/s per channel. 
Additionally, we used the large velocity range with calibration by means of the reference absorber 
of -Fe foil with a thickness of 7 m (the spectrum lines were also narrow and Lorentzian). This 
velocity range was used for the 90 K Ferrifol® Mössbauer spectrum measurement. The 
instrumental (systematic) errors for each spectrum point and for the hyperfine parameters were 
equivalent to 0.5 and 1 channel, respectively. If an error calculated with the fitting procedure 
(statistical or fitting error) for these parameters exceeded the instrumental (systematic) error, a 
larger error was used. The values of isomer shift are given relative to –Fe at 295 К.  
The Mössbauer spectra of Ferrifol® sample were measured at 20 K, 40 K and 60 K using a 
KFKI-type spectrometer with a triangular velocity reference signal and an APD close cycle liquid 
helium cryostat at the Eötvös Loránd University (Budapest). The 
57Со(Rh) source of ~0.8×109 Bq 
(Ritverc GmbH, St. Petersburg, Russian Federation) was used at room temperature. The spectrum 
was measured in transmission geometry with a moving source in the large velocity range and 
registered in 250-channel mirror spectra with further folding. Statistical count rates for the 
Ferrifiol® spectra were in the range ~(4.0–5.0)×105 counts per channel with the signal-to-noise 
ratios of 38–40. Calibration of the velocity scale was done with the same reference absorber of -Fe 
as mentioned above. The velocity resolution in these spectra was ~0.09–0.10 mm/s per channel. 
These spectra were fitted using MossWinn code [44] and UNIVEM-MS program to obtain 
qualitative characteristics only. The values of magnetic hyperfine field, Heff, were obtained in 
addition to above mentioned Mössbauer parameters. 
 
Results and discussion 
 
TEM image of Ferrifol® sample shown in Fig. 1a demonstrates dispersed nanoparticles (iron 
cores) with variety of shapes between spherical and ellipsoidal. The particles’ size distribution was 
estimated using the ratio between the major and minor axes of ellipsoid particles’ shape (Fig. 1b) 
and by particles’ diameter evaluated using spherical fit (Fig. 1c). These particles have sizes in the 
range of 2–6 nm. Similar ellipsoid shape with 6 nm average size of the iron cores was observed in 
another iron-polymaltose complex Ferrum Lek [47]. 
XRD pattern of Ferrifol® is shown in Fig. 2. A comparison of peak positions for akaganéite 
and ferrihydrite showed that the iron core in Ferrifol® consists of ferrihydrite instead of akaganéite 
which was observed in the other iron-polymaltose complexes Ferrum Lek and Maltofer® (see [40]). 
The mass loss and heat flow in Ferrifol® determined by TG are shown in Fig. 3. The weight 
of inorganic part of Ferrifol® was determined as ~24 % of the initial sample weight. This result 
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appeared to be similar to that obtained for Ferrum Lek and Maltofer® while smaller than the mass 
loss for ferritin (~33 %) [40]. The weights of the inorganic parts in Ferrifol® and ferritin will be 
used for the quantitative magnetization measurements shown below. 
 
 
Fig. 1. Transmission electron microscopy image of Ferrifol® (a), the ratio between the major and 
minor axes of ellipsoid particles’ shape (b) and distribution of particles’ diameter evaluated using 
spherical fit (c). 
 
The temperature dependence of zero-field-cooled (ZFC) and field-cooled (FC) magnetization 
M(T) curves measured at 250 Oe and the isothermal field dependence of the magnetization M(H) 
measured at 5 and 295 K are displayed in Fig. 4. A pronounced peak at 14 K is observed in ZFC 
plot Fig. 4a (inset) and the two curves merge at blocking temperature TB = 33 K. In that sense this 
behavior is very similar to pure ferritin shown in Fig. 4b. Above TB both curves up to 300 K 
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7 
exhibits a typical paramagnetic (PM) shape and adheres to the Curie-Weiss (CW) law: (T) = 0 
+C/(T–), where  = (M/H), 0 is the temperature independent part, C is the Curie constant, and  
is the CW temperature. The extracted PM parameters are: 0 =2.110
–6
 emu/g Oe, C = 0.0158(1) 
emu K/g Oe and  = –3.7(2) K. The negative  value indicates clearly the presence of anti-
ferromagnetic exchange forces in Ferrifol® at low temperatures below TB. 
 
 
Fig. 2. X-ray diffraction of Ferrifol® sample. Symbols “+” indicate the peak positions for 
ferrihydrite (ICDD 01-073-8408). 
 
 
Fig. 3. Thermogravimetry of Ferrifol® sample. 
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Fig. 4. Comparison of magnetization measurements for inorganic part (iron cores) in Ferrifol® and 
ferritin: zero-field-cooled (ZFC) and field-cooled (FC) curves measured at indicated fields (a and b) 
and isothermal magnetization curves (c, d and e). Exp is experimental points, Par is paramagnetic 
contribution, MS is the saturation magnetic moment, HC is coercive field. 
 
The isothermal M(H) curves measured at 5 and 295 K (Fig. 4c) confirm this picture. At 5 K, 
the magnetization first increases linearly up to 10–15 kOe and then tends to saturate. This M(H) plot 
clearly reveals an admixture of magnetic and PM components and can be fitted as: M(H) = MS + 
pH, where the saturation moment (corrected) MS = 1.29 emu/g, is the intrinsic magnetic phase(s) 
contribution, and pH (p = 2.210
–5
 emu T/g Oe) is the linear PM contribution (Fig. 4d). This MS 
is 20% higher than that of pure Ferritin shown in Fig. 4e. Thus, below TB an admixture of two 
   
Ferrifol® Ferritin 
   
 
Ferrifol® Ferrifol® 
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magnetic states exist, namely, part of the sample is PM and part seems to be anti-ferromagnetically 
ordered. On the other hand, M(H) at 295 K is linear with the slope of 7.65 emu T/g Oe, up to 50 
kOe (Fig. 4c), indicating a pure PM state above TB of the entire material. 
The room temperature X-band EMR spectrum of the original Ferrifol® powder (Fig. 5) 
reveals several groups of components. The signal group around B  1000 G may originate from 
magnetic particles whose easy magnetization axis tends to align along the externally applied 
magnetic field. The broad signal group at around B  2500 G may refer to magnetic particles with a 
random orientation of their easy magnetization axis, whereas the relatively sharp signal at B  3000 
G indicates the presence of paramagnetic or superparamagnetic particles in the sample. When the 
same sample is mixed with KBr powder (in order to ensure random orientation of easy 
magnetization axes), the signal group formerly around B  1000 G merges with the central (B  
2500–3000 G) region, and the peak of a very broad, low-amplitude signal becomes apparent in its 
former position (Fig. 6). The latter signal, having a peak-to-peak width of pp  3.7 kG at T = 290 
K, may refer to randomly oriented magnetic particles with a relatively large magnetic anisotropy 
field. 
 
 
Fig. 5. X-band EMR spectrum of original Ferrifol® powder measured at T = 290 K. 
 
With decreasing temperature this latter ferromagnetic resonance signal (referred to as signal 
“A” in the followings, see Fig. 6) shifts towards lower fields, reflecting a simultaneous increase in 
the effective magnetization of the corresponding particles. During the fit of the spectra the 
asymmetry of the corresponding signal was well accounted for by assuming that it originates from 
magnetic particles with a large negative cubic magnetocrystalline anisotropy. The intrinsic g factor 
of this signal at 290 K was derived to be 2.26, with a magnetic anisotropy field of BA = 2K1/MS  –
0.244 T, where K1 stands for the (apparently negative) first-order cubic magnetocrystalline 
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anisotropy constant and MS denotes the saturation magnetization. A possible source of this 
component is magnetite that is known to display negative cubic magnetocrystalline anisotropy at 
room temperature [48–50]. Taking K1 = –1.08×10
4 J/m3 and MS = 4.72×10
5 A/m (as found for 
synthetic single crystals of magnetite [48]), we get BA  –0.046 T, roughly 20% of the value we 
have deduced. However, ultrafine (10 nm in diameter) magnetite nanoparticles were shown to 
exhibit considerably larger magnitude (K1  –5.8×10
4 J/m3) of the effective first-order cubic 
magnetocrystalline anisotropy constant in ferrofluids [49], which value yields BA = 2K1/MS  –
0.246 T in good agreement with the value we found for signal “A”. Therefore, it is plausible to 
attribute signal “A” to a tiny amount of magnetite. 
The relatively narrow singlet “C” (Fig. 6) was fitted with a Lorentzian derivative 
characterized by g  2.15 and pp  175 G at 290 K. The absolute as well as the relative intensity of 
this singlet is clearly enhanced with decreasing temperature, which is the expected behavior in case 
of paramagnets for which the temperature dependence of the power of microwave absorption 
should reflect that of the static magnetic susceptibility. The corresponding particles may then also 
contribute to the non-saturating part of the magnetization curve of Ferrifol® at 5 K (Fig. 4). 
The signal group “B” can be associated with magnetic particles displaying different values of 
a moderate magnetic anisotropy field. This signal group could be fitted by assuming that the 
associated particles display uniaxial magnetic anisotropy with a distribution in their effective 
magnetic anisotropy field. Particle size distribution as well as diversity in the shape of the particles 
may both contribute to such a distribution in the effective magnetic anisotropy field. In the fits 
shown in Fig. 6, signal group “B” is composed of components displaying either negative or positive 
uniaxial magnetic anisotropy field. Negative uniaxial (magnetocrystalline) anisotropy (easy plane of 
magnetization) may be associated with ferrihydrite particles (with hexagonal crystal structure [51, 
52]) without strong anisometricity. At the same time, positive uniaxial anisotropy (easy 
magnetization axis) may develop in anisometric particles (Fig. 1) due to magnetic shape anisotropy. 
The Mössbauer spectra of Ferrifol® measured in the temperature range from 295 to 90 K and 
the spectrum of ferritin measured at 98 K are shown in Fig. 7. Recently, it was shown that non-
Lorentzian line shape of the 295 K and 220 K Ferrifol® spectra could be fitted using a distribution 
of quadrupole splittings with further decomposition of distribution shapes using at least 4 peaks that 
indicated slightly different 
57
Fe microenvironments in the iron core [43]. Therefore, we used the 
previously considered heterogeneous iron core model to fit the Mössbauer spectra of ferritin and its 
pharmaceutical analogues Ferrum Lek and Maltofer® as well [41, 42]. The results of the Ferrifol® 
spectra fits are shown in Fig. 7: all spectra were fitted with a superposition of five quadrupole 
doublets with similar isomer shifts, different quadrupole splitting and the same line width as a free 
parameter which was varied during the fit.  
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Fig. 6. X-band EMR spectra of Ferrifol® powder mixed with KBr powder and measured at the 
indicated temperatures (black dots), along with the subcomponents and fit envelop fitted to the 
spectra (solid lines). 
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Fig. 7. Mössbauer spectra of Ferrifol® measured in the temperature range from 295 K to 90 K and 
ferritin measured at 98 K. Indicated components are the results of the best fits. The differential 
spectra are shown on the bottom of the spectra. 
 
We can see that this fitting model developed for ferritin, Ferrum Lek and Maltofer® is also 
applied for Ferrifol® and fitted well all Mössbauer spectra in the range from 295 K to 90 K. Again, 
we observed an unusual line broadening as the temperature is decreased which is shown in Fig. 8 
for both Ferrifol® and ferritin. Earlier, we have shown that observed anomalous line broadening 
cannot be a result of: (i) the cryostat vibrations, (ii) sample particles vibrations in case of moving 
absorber and (iii) an increase of the effective samples thickness with temperature decrease [39].  
However, the effect of slowing down of magnetic relaxation in nanosized iron cores in 
Ferrifol® should be checked. For this reason, Mössbauer spectra of Ferrifol® were measured in a 
large velocity range at temperatures of 90 K, 60 K, 40 K and 20 K and compared with the 
Mössbauer spectrum of ferritin at 20 K (see Fig. 9). It is clearly seen that the magnetically split 
component appears in the Ferrifiol® spectrum below 60 K only: at 40 K A17 %, Heff~400 kOe 
while at 20 K A34 %, Heff~413 kOe. In case of the ferritin Mössbauer spectrum, a weak magnetic 
sextet (A17 %, Heff~380 kOe) can be seen at 20 K. This means that the anisotropy energy barrier 
   
   
  
T=295 K Ferrifol® T=220 K Ferrifol® T=170 K Ferrifol® 
T=140 K Ferrifol® T=125 K Ferrifol® T=105 K Ferrifol® 
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for the iron cores in ferritin is a bit smaller than that in Ferrifol®. Similar results were obtained by 
ZFC-FC magnetization measurements (Fig. 4) showed that the blocking temperature for Ferrifol® 
(~33 K) was higher than that for ferritin (~22 K). These facts indicate that the line broadening in the 
Mössbauer spectrum of Ferrifol® resulting from the magnetic relaxation factor should started at 
higher temperatures than that for ferritin. However, we can see from Fig. 8 that the line broadening 
starts for ferritin at so-called critical temperature T0 ~150 K while that for Ferrifol® is about ~138 
K. Therefore, we can exclude relaxation factor as the main reason of the unusual line broadening in 
the Mössbauer spectra of Ferrifol® with temperature decrease as suggested in [39, 42]. In this case 
anomalous line broadening could be related to some internal processes in the iron core which are 
more dominant at low temperatures down to 90 K.  
 
 
Fig. 8. Unusual temperature dependent line broadening observed for the Ferrifol® Mössbauer 
spectra in comparison with that of ferritin. T0 – is a conventional critical temperature of crossing 
two different slopes (indicated with dashed lines) for the line width temperature dependences. 
 
When comparing the decomposition of EMR spectra (Fig. 6) with that of the 
57
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EMR spectroscopy samples the magnetic state of the material is ca. 2 orders of magnitude shorter 
than the corresponding time characteristic to 
57
Fe Mössbauer spectroscopy. Consequently, particles 
that contribute with ferri- or ferromagnetic signals to the EMR spectrum may appear as a 
superparamagnetic component in the corresponding 
57
Fe Mössbauer spectrum. Furthermore, it 
should also be considered that while antiferromagnetic iron bearing materials may not produce an 
EMR signal, they can readily contribute to the 
57
Fe Mössbauer spectra. It should also be mentioned 
that the measured EMR spectra may also be contributed by signals originating from minute amounts 
of paramagnetic ions other than Fe
3+
, which possibility was not considered in the present analysis. 
 
 
Fig. 9. Mössbauer spectra of Ferrifol® at temperatures of 90 K, 60 K, 40 K and 20 K and ferritin at 
20 K measured in the large velocity range. Indicated components are the result of the best fits. The 
differential spectra are shown at the bottom of the fitted spectra. 
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Based on the heterogeneous iron core model for the fitting of the Mössbauer spectra of 
Ferrifol®, we can assign the quadrupole doublet with the smallest EQ value to the most close-
packed FeOOH regions/layers in the iron core while that with the largest EQ value can be related 
to the less close-packed FeOOH regions/layers. In this case we can consider the temperature 
dependence of  and EQ values for the corresponding quadrupole doublets related to different 
regions/layers in the iron core in the range from 295 K to 90 K as shown in Fig. 10. These 
dependences are similar to those observed earlier for ferritin, Ferrum Lek and Maltofer® [42]. The 
values of  demonstrate different character of temperature dependences for the two quadrupole 
doublets with the smallest EQ values and that of the rest three quadrupole doublets with 
intermediate and the largest EQ values, in which the  values unusually tend to decrease below 
120–140 K. An increase of EQ values with temperature demonstrates different behavior also. 
Three quadrupole doublets with the largest EQ values show much more rapid increase of EQ 
values below 120 K as compared to the two other quadrupole doublets. These results may be related 
to some structural disorders in the corresponding FeOOH regions/layers resulting in some 
variations in the 
57
Fe hyperfine parameters.  
 
 
Fig. 10. Temperature dependencies of Mössbauer hyperfine parameters for Ferrifol®:  doublet 1, 
 doublet 2,  doublet 3,  doublet 4,  doublet 5. 
 
Further, we compare temperature dependences of the relative areas of the Ferrifol® 
Mössbauer spectra components between 295 and 90 K (Fig. 11). It is interesting to observe different 
tendencies in the temperature dependences of A for different components. In case of the most close-
packed region/layer in the core (quadrupole doublet 1) the relative area increases when temperature 
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decreases while the second most close-packed region/layer in the core (quadrupole doublet 2) 
remains almost the same. In contrast, three less close-packed layers/regions demonstrate a tendency 
of the relative areas to decrease when temperature decreases. Therefore, we can suggest that the 
decrease with temperature of the less close-packed regions/layers in the core accompanies with 
increasing the most close-packed region/layer in the core. In this case the low-temperature 
rearrangements in the iron core may take place with variations (i) in the areas of these 
regions/layers and (ii) in corresponding Mössbauer hyperfine parameters. Moreover, this 
rearrangement can increase the internal dynamics in the core which accompanied by an anomalous 
line broadening and a decrease in the absorption effect below 125 K as can be seen in Fig. 7. This 
result may confirm earlier data of the EXAFS study of ferritin iron core, which demonstrated a 
considerable structural disorder in the core at low temperatures, which the authors supposed as a 
possible low temperature phase transition [53]. In any case, the obtained results confirm the 
heterogeneous iron core model to fit Mössbauer spectra of ferritin and its pharmaceutical analogues 
and associate different quadrupole doublets with more or less close-packed FeOOH regions/layers 
in the core. 
 
 
Fig. 11. Different variations of the relative areas of five quadrupole doublets obtained from the 
Mössbauer spectra of Ferrifol® with temperature decrease. 
 
To check this model, we obtained HRTEM images of both Ferrifol® (Fig. 12) and ferritin 
(Fig. 13) as well as the Fourier transforms (FT) of areas of ca. 5050 nm were calculated to 
characterize the average structure of the nanosized iron cores. The iron cores in these images 
constitute ordered domains with lattice periodicities between 2.0 and 2.7 Å for both Ferrifol® and 
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ferritin. However, while the FT of ferritin mostly contains discrete, point like maxima, indicating 
individual nanocrystalline domains (Fig. 13), the FT of Ferrifol® (Fig. 12b) is dominated by two 
broad and diffuse rings at 2.6 and 2.1 Å. This implies that the average structure of Ferrifol® iron 
cores is less ordered and/or their average domain size is smaller than those of ferritin. The rings on 
the FT of Ferrifol® are consistent with ferrihydrite.  
 
 
Fig. 12. High resolution transmission electron microscopy image of Ferrifol®: 5050 nm area (a), 
its Fourier transform demonstrating the diffuse rings due to the poorly ordered structure and/or the 
small average domain size (b) and enlarged area marked by white box in (a) with indicated lattice 
spacings of individual iron cores (c). 
 
 
Fig. 13. High resolution transmission electron microscopy image of ferritin (a) and the 
corresponding Fourier transform of 5050 nm area (b). The scale is the same as in Fig. 12. Some 
iron cores are enlarged in the insert. 
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To get a closer view of the ordering state of individual Ferrifol® iron cores, detailed HRTEM 
analysis was carried out (Fig. 14). Based on HRTEM, three types of lattice images could be 
distinguished. (1) In the most cases the actual orientation of crystalline nanosized iron cores allows 
the imaging of lattice periodicity in only one direction (e.g. Fig. 14a–c). This periodicity varies 
between 2.2 and 2.8 Å, which can be identified as the distance of Fe-O(H) layers in ferrihydrite 
structure. The variation of this distance indicates heterogeneity of the iron cores, probably related to 
the disordered structure. (2) In some cases, lattice fringes could be measured in two directions, 
which allow identification of crystal structure and orientation (e.g. Fig. 14d). (3) The third group 
comprises partially or fully disordered iron cores (Fig. 14e–i). These iron cores are either 
amorphous (e.g. Fig. 14h and i) being sometimes closely attached to nanocrystalline domains (Fig. 
14e) or exhibit a complex nanostructure with more and less ordered parts (Fig. 14f and g). As these 
particles are extremely small (20–30 Å in size, which are around 5–10 unit cells), it is difficult and 
maybe useless to interpret these variations in terms of crystal lattice. However, it can be stated that 
the Ferrifol® iron cores represent heterogeneous structures of different ordering states, which can 
be interpreted as sets of Fe-O(OH) layers without long range correlation. The nanoscale 
heterogeneity, the small domain size and the low overall degree of ordering might be related to an 
uneven distribution of iron atoms between O(OH) layers. Variation of oxidation state also cannot be 
excluded. Thus, HRTEM supports a complex heterogeneous iron core structure with different 
interlayer distances and distribution of iron atoms, as well as possible presence of tiny amount of 
iron oxides other than ferrihydrite or akaganéite in Ferrifol®, a pharmaceutical analogue of ferritin. 
 
Conclusion 
 
Pharmaceutical iron(III)-polymaltose complex Ferrifol® used for treatment of iron deficiency 
anemia was studied by means of transmission electron microscopy, X-ray diffraction, 
thermogravimetry, dc magnetization measurements, electron magnetic resonance and 
57
Fe 
Mössbauer spectroscopy in a wide temperature range and compared with similar results for ferritin 
and two other iron(III)-polymaltose complexes Ferrum Lek and Maltofer®.  
HRTEM of Ferrifol® revealed small domains of 2–6 nm without long range correlation and 
an uneven distribution of iron atoms in the interstitial sites of close-packed O(OH) layers was 
deduced. ZFC and FC magnetization measurements indicate anti-ferromagnetic behavior up to the 
blocking temperature of 33 K. At higher temperatures, the material seems to be paramagnetic. EMR 
spectra displayed components that could be associated with a tiny amount of magnetite, a 
paramagnetic species and ferrihydrite displaying a distribution in the uniaxial magnetic anisotropy 
field.  
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Fig. 14. Lattice images of individual Ferrifol® iron cores observed using high resolution 
transmission electron microscopy. Explanation is given in the text. 
 
The Mössbauer spectra of Ferrifol® measured in the temperature range from 295 K to 90 K 
were fitted using the heterogeneous iron core model, which appeared to be suitable also for our 
previously ferritin and its pharmaceutical analogues studies. The obtained spectral components (five 
quadrupole doublets) were related to the more and less close-packed iron core regions/layers in the 
Ferrifol® iron cores according to the value of quadrupole splitting. Anomalous temperature 
dependencies of some Mössbauer parameters with temperature decreasing were observed in this 
temperature range for Ferrifol® while slowing down of the magnetic relaxation led to magnetically 
split component appearance in the Mössbauer spectra below 60 K only. These observed anomalies 
were associated with the low temperature structural rearrangements of the more and less close-
packed FeOOH regions/layers in the iron cores. This rearrangement implies a decrease of the area 
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of less close-packed regions/layers which alteration into the more close-packed regions/layers leads 
to increase of the total area of the latter. 
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GRAPHICAL ABSTRACT 
 
 
 
 
The Mössbauer spectra of pharmaceutical ferritin analogue Ferrifol® (T=295–90 K) were fitted 
using five quadrupole doublets. The blocking temperature for the largest iron cores is 33 K. High 
resolution transmission electron microscopy shows the lattice periodicity in the Ferrifol® iron cores 
in the range 2.2–2.7 Å. 
 
 
  
 
 
T=170 K Ferrifol® Ferrifol® 
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HIGHLIGHTS 
 
Ferrifol® is an iron(III)-polymaltose pharmaceutical ferritin analogue 
 
Magnetization measurements of Ferrifol® demonstrate a blocking temperature at ~33 K 
 
The lattice periodicity in the Ferrifol® iron cores varies in the range 2.2–2.7 Å 
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